Juergen Wolf, MD, medical director, Center for Integrated Oncology (CIO) at the University Hospital Cologne, discusses the phase II findings of the GEOMETRY mono-1 study in patients with MET exon 14-mutated advanced non-small cell lung cancer.
Juergen Wolf, MD, medical director, Center for Integrated Oncology (CIO) at the University Hospital Cologne, discusses the phase II findings of the GEOMETRY mono-1 study in patients withMETexon 14-mutated advanced non-small cell lung cancer (NSCLC).
In findings from the GEOMETRY trial presented at the 2018 ESMO Congress, an overall response rate (ORR) of 72.0% was observed for the investigational MET inhibitor capmatinib (INC280) in treatment-naive patients and 39.1% in previously treated patients. The safety profile was tolerable, and results suggest that this agent may be beneficial to patients with exon 14 skipping mutations.
These first-line data are very exciting, Wolf says, as this ORR has never been reported in patients withMET
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More